The revised “Regulation on the Supervision and Administration of Medical Devices” (hereinafter referred to as the “New Regulation”) (enacted by the State Council of PRC on 7 March 2014) entered into force on 1 June 2014. The New Regulation replaces the former regulation enacted on 4 January 2000 (hereinafter referred to as the “Former Regulation”).
Although the New Regulation has lessened the requirements medical devices distributors of class I medical devices must fulfill in order to enter into the medical device industry, it has imposed further potential liability in the form of additional sanctions. Medical device companies should check carefully that all compliance criteria have been fulfilled. It can be expected that after the New Regulation comes in to force, the food and drug authorities will be visiting medical device companies more often to inspect their operations.
Compared with the Former Regulation, the New Regulation implements several key changes, including in relation to:
- Change in the approval for trading of medical devices and registration for medical devices
- Non compliance sanctions
- Third party logistics
- Import & Export
1. Change in approval for trading of medical devices and registration for medical devices
- Class I Medical Devices Licence: from registration to filing
The New Regulation has removed the registration requirement for Class I medical devices. Instead of a Medical Device Licence registration, only a filing is required with the local FDA (“Food and Drug Administration”).
For the filing, a medical device inspection report and a clinical assessment report must be submitted to the local FDA. Under the New Regulation, a self inspection report prepared by the applicant itself can be served as the inspection report and clinical documents or data for another similar product can be treated as the clinical evaluation report.
- Trading of Class I medical devices : cancellation of filing requirement
According to the Former Regulation, in order to carry out trading activities of Class I medical device, a filing must be made with the local FDA. The New Regulation has removed this filing requirement. This implies that all trading companies may carry out Class I medical devices trading activities without a Medical Devices Trading Licence, provided that the medical devices that they purchase and resell have been previously filed with the local FDA.
Trading of Class II medical devices: from approval to filing
Under the Former Regulation, trading of Class II medical devices is subject to an approval by the provincial FDA. The New Regulation changes this so that only a filing is required.
To better illustrate the above changes, please refer to the following table:
Click here to view table.
2. Non-compliance sanctions
The current legal basis for the sanctions for non compliant activities is not the Former Regulation, but predominantly another regulation issued by the State Council, the “Special Regulation to Reinforce the Administration for Security for Food and Other Products Published by the State Council”(effective as of 26 July 2007) (hereinafter referred to as the “Special Regulation”). As the Special Regulation is also published by the State Council and its publication post dates that of the Former Regulation, in practice, the Special Regulation is often used by authorities as the basis for sanctions.
The New Regulation has taken into account this practice and therefore the sanctions provisions are similar to those in the Special Regulation. The New Regulation has also clarified some sanctions which were not clearly stipulated under the Special Regulation. The New Regulation tends to impose more liabilities on the persons in charge of such non compliant activities.
The following table can reflect part of the sanctions modified in the New Regulation:
Click here to view table.
3. Third party logistics
According to the current practice, if a company intends to act as third party logistics service provider, the company shall apply for a Medical Device Third Party Qualification. This regime has been implemented as a pilot scheme to govern these kinds of services, which have become popular in China, but it has not yet been clearly legislated.
However, the New Regulation does not provide a legal basis for such regime either. We noticed that in the draft Measures on the supervision and administration of medical devices for public comments, this regime would probably be changed into the administration of medical trading licence, as CFDA considers that the third party logistics service is also one of the forms of trading activities. This could explain why this issue is not clearly mentioned in the New Regulation.
4. Import and Export
Under the “Notice on Administration of Foreign Medical Device Label and Package published by State Food and Drug Administration” (effective as of 1 April 2013), imported medical devices shall not be distributed or used in China if no Chinese label and package signs are affixed.
Such provision has led to some confusion, especially as to the legitimacy of labeling activities in free trade zones for imported medical devices, because free trade zones are considered as Chinese territory by CFDA but as outside of Chinese territory by customs. To affix a label in a free trade zone can reduce the costs of such additional manufacturing process abroad, but will inevitably give rise to legal uncertainty as to whether such labeling is considered as made in China or made abroad, which may lead to different regulatory requirements for medical devices.
The New Regulation provides that foreign medical devices shall not be “imported” if no Chinese package insert and Chinese label are affixed. As the word “import” is not defined in the New Regulation, this may impliedly give a legal basis that labeling can be made in a free trade zone, as products are not imported into China when labeling is done in the free trade zone. More explanation or practice is expected to clarify this provision.
CFDA issued respectively two circulars to govern the administration of exported medical devices in 2004 and 2008 where a medical device export certificate must be applied with CFDA. However, the New Regulation still does not provide any provision to support such practice.
The New Regulation also fails to provide further clarity on the administration of medical devices by Chinese companies upon the request of a foreign client (so-called OEM manufacturing). It is uncertain whether a medical devices company which only carries out OEM manufacturing activities for exported medical devices needs to apply for a medical devices manufacturing licence.
Despite the above changes, the New Regulation does not provide for the possibility of the transfer of a medical devices licence through technology transfer, as is permitted in relation to pharmaceuticals.
Without such regime, it would be not possible to convert an imported medical devices licence into a domestic medical devices licence if a foreign investor wanted to relocate the manufacture of such medical devices to China in a relatively fast procedure. The foreign investor would have to apply for another domestic medical devices licence from scratch. This is more cumbersome for foreign investors who wish to reduce manufacturing costs by relocating part or all of their manufacturing capacity to China, and is not favorable to encouraging technology development in medical devices areas.
The New Regulation clarifies some uncertainties in medical devices administration but also leaves quite a few uncertainties which have not yet been resolved in practice but are extremely important for foreign investors to carry out their business in China, such as OEM manufacturing, import and export, labeling, and transfer of imported medical devices to domestic ones. However, how to implement the New Regulation is still unclear, as CFDA is now revising a series of measures in connection with the New Regulation, which will be used as supportive measures to implement the New Regulation. These include measures on the supervision and administration of manufacturing of medical devices, measures on the supervision and administration of trading of medical devices, measures related to package inserts, packaging, labeling of medical devices, measures related to the administration of registration and filing of medical devices, and others. These measures will form an integral part of the new regime to govern medical devices under the New Regulation.